This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Background Previous randomised controlled trials comparing bladder preservation with
radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual …

Background BC2001, the largest randomised trial of bladder-sparing treatment for muscle-
invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by …

Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites
such as prostate and breast cancer. Much research effort is being directed towards more …

Background Muscle-invasive bladder cancer (MIBC) has a poor prognosis.
Chemoradiotherapy (CRT) in selected patients has comparable results to radical …

Simple Summary Immunotherapy with immune checkpoint inhibition (ICI) has provided
durable treatment responses in advanced, metastatic, bladder cancer patients. The first trials …

Purpose Curative radio-chemotherapy is recognized as a standard treatment option for
muscle-invasive bladder cancer (MIBC). Nevertheless, the technical aspects for MIBC …

Radical cystectomy with perioperative chemotherapy remains the gold standard treatment
for MIBC patients. Nevertheless, BSS can be considered a viable option in selected patients …

The standard of care for non-muscle-invasive bladder cancer (NMIBC) is transurethral
resection followed by risk stratified use of intravesical immune-or chemotherapy and for …